PMID- 20700860
OWN - NLM
STAT- MEDLINE
DCOM- 20110610
LR  - 20211203
IS  - 1098-8785 (Electronic)
IS  - 0735-1631 (Linking)
VI  - 28
IP  - 2
DP  - 2011 Feb
TI  - Fetal and neonatal alloimmune thrombocytopenia: harvesting the evidence to 
      develop a clinical approach to management.
PG  - 137-44
LID - 10.1055/s-0030-1263296 [doi]
AB  - Neonatal alloimmune thrombocytopenia (NAIT) is the most common cause of severe 
      thrombocytopenia in an otherwise healthy newborn. The most serious complication 
      is intracranial hemorrhage, which can occur either in the fetus or the newborn. 
      Despite the known serious sequelae, both antenatal management and neonatal 
      treatment modalities are plagued by the lack of gold standard evidence to 
      appropriately direct therapy. Maternal, risk-based therapeutic approaches range 
      from invasive protocols to relatively benign noninvasive strategies to avoid 
      serious procedural complications. Intravenous immunoglobulin (IVIG) with or 
      without steroids and fetal blood sampling constitute the mainstay of antenatal 
      management. Neonatal interventions principally focus on the use of 
      antigen-negative compatible or random donor platelets and IVIG. While awaiting 
      the results of controlled trials, each institution must develop a standardized, 
      collaborative, multidisciplinary approach to the screening, diagnostic 
      evaluation, and management of unexpected and anticipated NAIT based on 
      experience, product availability, and emerging scientific data.
CI  - (c) Thieme Medical Publishers.
FAU - Symington, Amanda
AU  - Symington A
AD  - Hamilton Health Sciences, McMaster Children's Hospital, Neonatal Division, 
      McMaster University, Ontario, Canada.
FAU - Paes, Bosco
AU  - Paes B
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20100810
PL  - United States
TA  - Am J Perinatol
JT  - American journal of perinatology
JID - 8405212
RN  - 0 (Antigens, Human Platelet)
RN  - 0 (ITGB3 protein, human)
RN  - 0 (Integrin beta3)
SB  - IM
MH  - Antigens, Human Platelet/*immunology
MH  - Female
MH  - Fetal Therapies/adverse effects/*methods
MH  - Humans
MH  - Incidence
MH  - Infant, Newborn
MH  - Integrin beta3
MH  - Pregnancy
MH  - Prenatal Diagnosis
MH  - Thrombocytopenia, Neonatal Alloimmune/diagnosis/*epidemiology/*immunology/therapy
EDAT- 2010/08/12 06:00
MHDA- 2011/06/11 06:00
CRDT- 2010/08/12 06:00
PHST- 2010/08/12 06:00 [entrez]
PHST- 2010/08/12 06:00 [pubmed]
PHST- 2011/06/11 06:00 [medline]
AID - 10.1055/s-0030-1263296 [doi]
PST - ppublish
SO  - Am J Perinatol. 2011 Feb;28(2):137-44. doi: 10.1055/s-0030-1263296. Epub 2010 Aug 
      10.